{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:31:52Z","timestamp":1787668312174,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05550-z","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:58:11Z","timestamp":1780905491000},"page":"18283-18297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug-associated cytokine release syndrome: a FAERS pharmacovigilance study with complementary transcriptomic analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Ye","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxiang","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongni","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"5550_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001229","volume":"8","author":"P Ataca Atilla","year":"2020","unstructured":"Ataca Atilla P, McKenna MK, Tashiro H, Atilla Eea et al (2020) Modulating TNF\u03b1 activity allows transgenic IL15-expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer 8:e001229. https:\/\/doi.org\/10.1136\/jitc-2020-001229","journal-title":"J Immunother Cancer"},{"key":"5550_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"5550_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/cancers17071054","volume":"17","author":"J Canzian","year":"2025","unstructured":"Canzian J, Conforti F, Jacobs F et al (2025) Sex-related differences in immunotherapy toxicities: insights into dimorphic responses. Cancers (Basel) 17:1054. https:\/\/doi.org\/10.3390\/cancers17071054","journal-title":"Cancers (Basel)"},{"key":"5550_CR4","doi-asserted-by":"publisher","first-page":"21386","DOI":"10.1038\/s41598-024-71977-0","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen Y, Ren X, Dai Y, Wang Y (2024) Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA Adverse Event Reporting System. Sci Rep 14:21386. https:\/\/doi.org\/10.1038\/s41598-024-71977-0","journal-title":"Sci Rep"},{"key":"5550_CR5","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","volume":"25","author":"E Drent","year":"2019","unstructured":"Drent E, Poels R, Ruiter R et al (2019) Combined CD28 and 4\u20131BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells. Clin Cancer Res 25:4014\u20134025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2559","journal-title":"Clin Cancer Res"},{"key":"5550_CR6","volume-title":"Guideline on the use of statistical signal detection methods in the EudraVigilance data analysis system","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency (2012) Guideline on the use of statistical signal detection methods in the EudraVigilance data analysis system. European Medicines Agency, London"},{"key":"5550_CR7","unstructured":"Food and Drug Administration (2026a) FDA\u2019s Adverse Event Reporting System (FAERS). https:\/\/www.fda.gov\/drugs\/surveillance\/fdas-adverse-event-reporting-system-faers. Accessed 9 Mar 2026"},{"key":"5550_CR8","unstructured":"Food and Drug Administration (2026b) FDA Adverse Event Monitoring System (AEMS) quarterly data extract files. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 9 Mar 2026"},{"key":"5550_CR9","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D (2019) Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 25:e123\u2013e127. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756","journal-title":"Biol Blood Marrow Transplant"},{"key":"5550_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL (2020) Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 146:940\u2013948. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.025","journal-title":"J Allergy Clin Immunol"},{"key":"5550_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200746120-00005","volume":"46","author":"M Joerger","year":"2007","unstructured":"Joerger M, Huitema ADR, Richel DJ et al (2007) Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 46:1051\u20131068. https:\/\/doi.org\/10.2165\/00003088-200746120-00005","journal-title":"Clin Pharmacokinet"},{"key":"5550_CR12","doi-asserted-by":"publisher","first-page":"630066","DOI":"10.3389\/fimmu.2020.630066","volume":"11","author":"TN J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen TN, Kovats S, Lotter H (2020) Editorial: effects of androgens on immunity to self and foreign. Front Immunol 11:630066. https:\/\/doi.org\/10.3389\/fimmu.2020.630066","journal-title":"Front Immunol"},{"issue":"6","key":"5550_CR13","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jaad.2025.02.031","volume":"92","author":"A Joshi","year":"2025","unstructured":"Joshi A, Gawey L, Saadi C et al (2025) Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database. J Am Acad Dermatol 92(6):1434\u20131435. https:\/\/doi.org\/10.1016\/j.jaad.2025.02.031","journal-title":"J Am Acad Dermatol"},{"key":"5550_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.14791\/btrt.2024.0037","volume":"12","author":"A Ju","year":"2024","unstructured":"Ju A, Choi S, Jeon Y, Kim K (2024) Lymphodepletion in chimeric antigen receptor T-cell therapy for solid tumors: a focus on brain tumors. Brain Tumor Res Treat 12:208\u2013220. https:\/\/doi.org\/10.14791\/btrt.2024.0037","journal-title":"Brain Tumor Res Treat"},{"key":"5550_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70:86\u2013104. https:\/\/doi.org\/10.3322\/caac.21596","journal-title":"CA Cancer J Clin"},{"key":"5550_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3389\/fimmu.2015.00635","volume":"6","author":"D Khan","year":"2015","unstructured":"Khan D, Ansar Ahmed S (2015) The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. Front Immunol 6:635. https:\/\/doi.org\/10.3389\/fimmu.2015.00635","journal-title":"Front Immunol"},{"key":"5550_CR17","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16:626\u2013638. https:\/\/doi.org\/10.1038\/nri.2016.90","journal-title":"Nat Rev Immunol"},{"key":"5550_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/14740338.2025.2470875","volume":"24","author":"X Le","year":"2025","unstructured":"Le X, Zhang Y, Ma J (2025) Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database. Expert Opin Drug Saf 24:821\u2013830. https:\/\/doi.org\/10.1080\/14740338.2025.2470875","journal-title":"Expert Opin Drug Saf"},{"key":"5550_CR19","doi-asserted-by":"publisher","first-page":"1303935","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado Vea et al (2023) Lymphodepletion \u2013 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol 14:1303935. https:\/\/doi.org\/10.3389\/fimmu.2023.1303935","journal-title":"Front Immunol"},{"issue":"1","key":"5550_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody Vea et al (2023) CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer 22:20. https:\/\/doi.org\/10.1186\/s12943-023-01723-z","journal-title":"Mol Cancer"},{"key":"5550_CR21","doi-asserted-by":"publisher","first-page":"1357716","DOI":"10.3389\/fimmu.2024.1357716","volume":"15","author":"GH Martin","year":"2024","unstructured":"Martin GH, Gonon A, Martin-Jeantet Pea et al (2024) Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model. Front Immunol 15:1357716. https:\/\/doi.org\/10.3389\/fimmu.2024.1357716","journal-title":"Front Immunol"},{"key":"5550_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner Jea et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378:439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"key":"5550_CR23","unstructured":"MedDRA (2024) Support documentation: english. https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english. Accessed 5 Dec 2024"},{"key":"5550_CR24","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","volume":"7","author":"M Mhibik","year":"2023","unstructured":"Mhibik M, Gaglione EM, Eik D et al (2023) Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Adv 7:4089\u20134101. https:\/\/doi.org\/10.1182\/bloodadvances.2022009517","journal-title":"Blood Adv"},{"key":"5550_CR25","doi-asserted-by":"publisher","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M et al (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6","DOI":"10.1038\/s41577-021-00547-6"},{"key":"5550_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li Bea et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375\u20132391. https:\/\/doi.org\/10.1093\/annonc\/mdv383","journal-title":"Ann Oncol"},{"key":"5550_CR27","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett Nea et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"5550_CR28","doi-asserted-by":"publisher","first-page":"779915","DOI":"10.3389\/fendo.2022.779915","volume":"13","author":"TA Olsen","year":"2022","unstructured":"Olsen TA, Zhuang TZ, Caulfield S et al (2022) Advances in knowledge and management of immune-related adverse events in cancer immunotherapy. Front Endocrinol (Lausanne) 13:779915. https:\/\/doi.org\/10.3389\/fendo.2022.779915","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5550_CR29","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ajh.27069","volume":"98","author":"SY Ong","year":"2023","unstructured":"Ong SY, Pak S, Mei Mea et al (2023) Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. Am J Hematol 98:1751\u20131761. https:\/\/doi.org\/10.1002\/ajh.27069","journal-title":"Am J Hematol"},{"key":"5550_CR30","first-page":"212","volume":"6","author":"LA Pachella","year":"2015","unstructured":"Pachella LA, Madsen LT, Dains JE (2015) The toxicity and benefit of various dosing strategies for interleukin-2 in metastatic melanoma and renal cell carcinoma. J Adv Pract Oncol 6:212\u2013221","journal-title":"J Adv Pract Oncol"},{"issue":"1","key":"5550_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2051-1426-2-13","volume":"2","author":"R Payne","year":"2014","unstructured":"Payne R, Glenn L, Hoen Hea et al (2014) Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a community hospital biotherapy program. J Immunother Cancer 2:13. https:\/\/doi.org\/10.1186\/2051-1426-2-13","journal-title":"J Immunother Cancer"},{"key":"5550_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"E Pinto","year":"2025","unstructured":"Pinto E, Lione L, Compagnone M et al (2025) From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J Transl Med 23:10. https:\/\/doi.org\/10.1186\/s12967-024-06052-3","journal-title":"J Transl Med"},{"key":"5550_CR33","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S (2023) Cancer immunotherapies: advances and bottlenecks. Front Immunol 14:1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476","journal-title":"Front Immunol"},{"key":"5550_CR34","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"5550_CR35","doi-asserted-by":"publisher","first-page":"1385501","DOI":"10.3389\/fimmu.2024.1385501","volume":"15","author":"P Sanchez-Solares","year":"2024","unstructured":"Sanchez-Solares P, Vera-Gomez R, Lopez-Herrera MV et al (2024) Hormones and B-cell development in health and autoimmunity. Front Immunol 15:1385501. https:\/\/doi.org\/10.3389\/fimmu.2024.1385501","journal-title":"Front Immunol"},{"issue":"17","key":"5550_CR36","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.3390\/math12172705","volume":"12","author":"R Sarkar","year":"2024","unstructured":"Sarkar R, Sun J (2024) Improved Apriori method for safety signal detection using post-marketing clinical data. Mathematics (Basel) 12:2705. https:\/\/doi.org\/10.3390\/math12172705","journal-title":"Mathematics (Basel)"},{"key":"5550_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000542461","volume":"70","author":"C Seydoux","year":"2025","unstructured":"Seydoux C, Briki M, Wagner AD et al (2025) Importance of sex-dependent differences for dosing selection and optimization of chemotherapeutic drugs. Chemotherapy 70:92\u2013101. https:\/\/doi.org\/10.1159\/000542461","journal-title":"Chemotherapy"},{"key":"5550_CR38","doi-asserted-by":"publisher","first-page":"1190379","DOI":"10.3389\/fimmu.2023.1190379","volume":"14","author":"D Shah","year":"2023","unstructured":"Shah D, Soper B, Shopland L (2023) Cytokine release syndrome and cancer immunotherapies \u2013 historical challenges and promising futures. Front Immunol 14:1190379. https:\/\/doi.org\/10.3389\/fimmu.2023.1190379","journal-title":"Front Immunol"},{"key":"5550_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"key":"5550_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70831","volume":"14","author":"JY Tan","year":"2025","unstructured":"Tan JY, Yeo YH, Kin Hea et al (2025) Sex differences in outcomes of chimeric antigen receptor (CAR) T-cell therapy. Cancer Med 14:e70831. https:\/\/doi.org\/10.1002\/cam4.70831","journal-title":"Cancer Med"},{"key":"5550_CR41","doi-asserted-by":"publisher","first-page":"103388","DOI":"10.1016\/j.ebiom.2021.103388","volume":"67","author":"TE Tavolara","year":"2021","unstructured":"Tavolara TE, Niazi MKK, Gower Aea et al (2021) Deep learning predicts gene expression as an intermediate data modality to identify susceptibility patterns in Mycobacterium tuberculosis infected Diversity Outbred mice. EBioMedicine 67:103388. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103388","journal-title":"EBioMedicine"},{"key":"5550_CR42","doi-asserted-by":"publisher","first-page":"807050","DOI":"10.3389\/fimmu.2022.807050","volume":"13","author":"SH Tay","year":"2022","unstructured":"Tay SH, Toh MMX, Thian Yea et al (2022) Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol 13:807050. https:\/\/doi.org\/10.3389\/fimmu.2022.807050","journal-title":"Front Immunol"},{"key":"5550_CR43","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/andr.13416","volume":"11","author":"S Vancolen","year":"2023","unstructured":"Vancolen S, S\u00e9bire G, Robaire B (2023) Influence of androgens on the innate immune system. Andrology 11:1237\u20131244. https:\/\/doi.org\/10.1111\/andr.13416","journal-title":"Andrology"},{"key":"5550_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.585","volume":"2","author":"Q Wang","year":"2022","unstructured":"Wang Q, Li M, Wu T, Li Lea et al (2022) Exploring epigenomic datasets by ChIPseeker. Curr Protoc 2:e585. https:\/\/doi.org\/10.1002\/cpz1.585","journal-title":"Curr Protoc"},{"key":"5550_CR45","doi-asserted-by":"publisher","first-page":"1140541","DOI":"10.3389\/fimmu.2023.1140541","volume":"14","author":"AX Wang","year":"2023","unstructured":"Wang AX, Ong XJ, D\u2019Souza C et al (2023) Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Front Immunol 14:1140541. https:\/\/doi.org\/10.3389\/fimmu.2023.1140541","journal-title":"Front Immunol"},{"key":"5550_CR46","doi-asserted-by":"publisher","unstructured":"Wang M, Chen X, Liu Zea, Liu S et al (2025) Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data. EClinicalMedicine 29:103385. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103385","DOI":"10.1016\/j.eclinm.2025.103385"},{"key":"5550_CR47","doi-asserted-by":"publisher","first-page":"2349796","DOI":"10.1080\/07853890.2024.2349796","volume":"56","author":"SE Willyanto","year":"2024","unstructured":"Willyanto SE, Alimsjah YA, Tanjaya K et al (2024) Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis. Ann Med 56:2349796. https:\/\/doi.org\/10.1080\/07853890.2024.2349796","journal-title":"Ann Med"},{"key":"5550_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2385489","volume":"24","author":"X Xi","year":"2024","unstructured":"Xi X, Yan X, Chen Y et al (2024) Cytokine release syndrome associated with immune checkpoint inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS. Expert Opin Drug Saf 24:1\u20138. https:\/\/doi.org\/10.1080\/14740338.2024.2385489","journal-title":"Expert Opin Drug Saf"},{"key":"5550_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004400","volume":"10","author":"Y Yamaguchi","year":"2022","unstructured":"Yamaguchi Y, Gibson J, Ou Kea et al (2022) PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages. J Immunother Cancer 10:e004400. https:\/\/doi.org\/10.1136\/jitc-2021-004400","journal-title":"J Immunother Cancer"},{"key":"5550_CR50","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/oncolo\/oyaf298","volume":"30","author":"K Yamaoka","year":"2025","unstructured":"Yamaoka K, Masago S, Uchida M et al (2025) Adverse events of antibody-drug conjugates: comparative analysis of agents with a common payload using the adverse event spontaneous reporting database. Oncologist 30:298. https:\/\/doi.org\/10.1093\/oncolo\/oyaf298","journal-title":"Oncologist"},{"key":"5550_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-1-0716-0301-7_11","volume":"2117","author":"G Yu","year":"2020","unstructured":"Yu G (2020) Gene ontology semantic similarity analysis using GOSemSim. Methods Mol Biol 2117:207\u2013215. https:\/\/doi.org\/10.1007\/978-1-0716-0301-7_11","journal-title":"Methods Mol Biol"},{"issue":"2","key":"5550_CR52","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips Eea et al (2021) Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract 9(2):819\u2013829. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5550_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011807","volume":"13","author":"X Yu","year":"2025","unstructured":"Yu X, Jain MD, Menges Mea et al (2025) Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. J Immunother Cancer 13:e011807. https:\/\/doi.org\/10.1136\/jitc-2025-011807","journal-title":"J Immunother Cancer"},{"key":"5550_CR54","doi-asserted-by":"publisher","first-page":"1231320","DOI":"10.3389\/fphar.2023.1231320","volume":"17","author":"L Zhang","year":"2023","unstructured":"Zhang L, Mao W, Liu Dea et al (2023) Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS). Front Pharmacol 17:1231320. https:\/\/doi.org\/10.3389\/fphar.2023.1231320","journal-title":"Front Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05550-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05550-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05550-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:03:09Z","timestamp":1787666589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05550-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5550"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05550-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the preparation of this work, the authors used ChatGPT (OpenAI) in order to improve language phrasing, grammar, and overall readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":1,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}